Fig. 6: Lsd1 is required for endocrine cell formation in mice during a short window in early pancreatic development.
a Strategy for conditional Lsd1 deletion in embryonic pancreatic progenitors of mice (Lsd1Δpan mice). Yellow boxes: exons; green triangles: loxP sites. b Immunofluorescent staining for Pdx1 at embryonic day (e) 12.5, Lsd1 and chromogranin A (ChgA) or Sox9 and Ngn3 at e15.5, and Lsd1, insulin (Ins) and glucagon (Gcg) at postnatal day (P) 0 in control and Lsd1Δpan mice (representative images, n = 6 embryos per genotype). Boxed areas are shown in higher magnification. Scale bar, 50 µm. c Quantification of pancreatic epithelial area at e12.5 and e15.5 and Ngn3+ cells relative to epithelial area. Data are shown as means ± S.E.M. (n = 3 embryos per genotype; source data are provided as a Source Data file). P = 0.65, 0.02, and 0.39, respectively, Student’s t-test, 2 sided. d Immunofluorescent staining for Ins with somatostatin (Sst), pancreatic polypeptide (Ppy) and ghrelin (Ghrl) at P0 in control and Lsd1Δpan mice. Scale bar, 25 µm. e Strategy for tamoxifen-inducible Lsd1 deletion in embryonic pancreatic progenitors of mice at e10.5 (Lsd1Δearly) and e12.5 (Lsd1Δlate). Yellow boxes: exons; green triangles: loxP sites. f Immunofluorescent staining for Lsd1, Ins and Gcg at e18.5 in control, Lsd1Δearly and Lsd1Δlate mice (representative images, n = 3 embryos per genotype). Boxed areas are shown in higher magnification. Scale bar, 50 µm. g Immunofluorescent staining for Lsd1 and EpCAM (left panels) and RNAscope in situ hybridization for HoxA1 (right panels, adjacent sections to left panels) in control and Lsd1Δearly embryos at e12.5 (representative images, n = 3 Lsd1Δearly embryos and n = 6 control embryos). Bottom images show higher magnification. Scale bar, 50 µm.
